US Patent

US11712459 — Dosing regimens for treatment of fungal infections

Method of Use · Assigned to Cidara Therapeutics Inc · Expires 2037-03-15 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects dosing regimens for the treatment of fungal infections using CD101 or a pharmaceutical acceptable salt or neutral form thereof.

USPTO Abstract

The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).

Drugs covered by this patent

rezafungin-acetate (REZAFUNGIN ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3566`	—	rezafungin-acetate

Patent Metadata

Patent number: US11712459
Jurisdiction: US
Classification: Method of Use
Expires: 2037-03-15
Drug substance claim: No
Drug product claim: Yes
Assignee: Cidara Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.